Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 66

Sort by

Sort Order Select

Journal Articles

How I treat newly diagnosed T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma in children

David T. Teachey, David O’Connor

Blood (2020) 135 (3): 159–166.

https://doi.org/10.1182/blood.2019001557

Published: 2020

Journal Articles

CXCR4 Inhibition with BL-8040 in Combination with Nelarabine in Patients with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia / Lymphoblastic Lymphoma

Geoffrey L. Uy, MD, Tapan M. Kadia, MD, Wendy Stock, MD, Jonathan E Brammer, MD, Osnat Bohana-Kashtan, PhD, Abi Vainstein, Ella Sorani, PhD, Hemda Chen, PharmD, John F. DiPersio, MD PhD, Daniel C. Link, MD

Blood (2019) 134 (Supplement_1): 2630.

https://doi.org/10.1182/blood-2019-127121

Published: 2019

Journal Articles

Characteristics and Clinical Outcomes of Patients with Acute Lymphoblastic Leukemia with KMT2A ( MLL ) Rearrangement

Blood (2019) 134 (Supplement_1): 2582.

https://doi.org/10.1182/blood-2019-130864

Published: 2019

Journal Articles

CXCR4 Blockade By BL-8040 in T Cell Acute Lymphoblastic Leukemia Decreases Mitochondrial Mass and Induces Non-Apoptotic Cell Death

Jun Xia, PhD, Stephanie Sun, Matthew RM Jotte, Geoffrey L. Uy, MD, Osnat Bohana-Kashtan, PhD, Ella Sorani, PhD, Abi Vainstein, Amnon Peled, PhD, Daniel C. Link, MD

Blood (2019) 134 (Supplement_1): 2745.

https://doi.org/10.1182/blood-2019-128881

Published: 2019

Journal Articles

Pediatric-Inspired Chemotherapy Incorporating Pegaspargase Is Safe and Results in High Rates of MRD Negativity in Adults Ages 18-60 with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Mark Blaine Geyer, MD, Ellen K. Ritchie, MD, Arati V. Rao, MD, M. Isabella Cazacu, Shreya Vemuri, Martin S. Tallman, MD, Dan Douer, MD, Jae H. Park, MD

Blood (2018) 132 (Supplement 1): 4013.

https://doi.org/10.1182/blood-2018-99-115486

Published: 2018

Journal Articles

The Impact of Minimal Residual Disease (MRD) Status at Day 28 in Predicting Relapse in Adults with Acute Lymphoblastic Leukemia in the Real World Setting

Bradley Walker Christensen, MD, Daniel C Pipilas, MD, Olalekan O. Oluwole, MBBS, MPH

Blood (2018) 132 (Supplement 1): 4027.

https://doi.org/10.1182/blood-2018-99-119342

Published: 2018

Journal Articles

The CXCR4 Antagonist, BL8040, Is Highly Active Against Human T-ALL in Preclinical Models

Jun Xia, PhD, Matthew RM Jotte, Stephanie Sun, Geoffrey L. Uy, MD, Abi Vainstein, Ella Sorani, PhD, Osnat Bohana-Kashtan, PhD, Stephen Shaw, PhD, Daniel C. Link, MD

Blood (2018) 132 (Supplement 1): 2700.

https://doi.org/10.1182/blood-2018-99-117213

Published: 2018

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) for Children and Young Adults with T-Cell Acute Lymphoblastic Leukemia (T-ALL) Treated at Investigator Discretion: A Report from Children's Oncology Group (COG) AALL0434

Stuart S. Winter, MD, Meenakshi Devidas, PhD, Brent Wood, MD PhD, Zhiguo Chen, MS, Natia Esiashvili, MD, Barbara L Asselin, MD, Mignon L. Loh, MD, Karen R. Rabin, MD PhD, Elizabeth A. Raetz, MD, Patrick A. Zweidler-McKay, MD PhD, Kirk R. Schultz, MD, Naomi Winick, MD, William L. Carroll, MD, Stephen P. Hunger, MD, Kimberly P. Dunsmore, MD

Blood (2018) 132 (Supplement 1): 659.

https://doi.org/10.1182/blood-2018-99-112146

Published: 2018

Journal Articles

Daratumumab in Combination with Vincristine or Nelarabine As Effective Salvage Therapy for Patients with Acute Lymphoblastic Leukemia at High Risk of Relapse

Yishai Ofran, MD, Chezi Ganzel, MD, Shimrit Harlev, MD PhD, Ilana Slouzkey, PhD, Ofrat Beyar Katz, MD, Michal Hayun, PhD, Mira Kharit, MD, Jacob M. Rowe, MD, Avraham Frisch, MD

Blood (2018) 132 (Supplement 1): 5206.

https://doi.org/10.1182/blood-2018-99-111258

Published: 2018

Journal Articles

Children's Oncology Group (COG) AALL0434: Successful Disease Control without Cranial Radiation in Newly Diagnosed T Lymphoblastic Lymphoma (T-LL)

Robert James Hayashi, Stuart S. Winter, MD, Kimberly P. Dunsmore, MD, Meenakshi Devidas, PhD, Brent Wood, MD PhD, Michelle L. Hermiston, MD PhD, David T Teachey, MD, Sherrie L. Perkins, MD PhD, Rodney R. Miles, MD PhD, Elizabeth A. Raetz, MD, Mignon L. Loh, MD, Naomi Winick, MD, William L. Carroll, MD, Stephen P. Hunger, MD, Megan S. Lim, MD,PhD, Catherine M. Bollard, MD, Thomas G. Gross, MD PhD

Blood (2018) 132 (Supplement 1): 1000.

https://doi.org/10.1182/blood-2018-99-113481

Published: 2018

Journal Articles

RAS and TP53 , Not NOTCH1 , Can Predict Survival in Adults with Acute T-Cell Lymphoblastic Leukemia Treated with Hypercvad

Ali Sakhdari, MD MSc, Sanam Loghavi, MD, Rashmi Kanagal-Shamanna, MD, C. Cameron Yin, MD PhD, Zhuang Zuo, MD, Mark Routbort, MD PhD, Keyur P. Patel, MBBS, PhD, Raja Luthra, PhD, L. Jeffrey Medeiros, MD, Chi Young Ok, MD

Blood (2018) 132 (Supplement 1): 4085.

https://doi.org/10.1182/blood-2018-99-119017

Published: 2018

Journal Articles

Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia in Real-World US Practices

Thomas W. LeBlanc, MD MA, Azah Borham, PharmD, Yun Su, MD MPH, MS, Karin Chun Hayes, Russel Fielding, Michael Benigno, MA, Joseph C. Cappelleri, PhD MPH, MS

Blood (2017) 130 (Supplement 1): 1328.

https://doi.org/10.1182/blood.V130.Suppl_1.1328.1328

Published: 2017

Journal Articles

Outcomes with Augmented Hyper-CVAD (AHCVAD), a Pediatric Inspired HCVAD-Based Regimen, for Adults Younger Than 50 Years of Age with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

James K McCloskey, MD, Genique Stanislaus, ANP, Jamie L. Koprivnikar, MD, Tracy Andrews, PhD, Jones Elizabeth, Danielle Marcotulli, APN, Grace Perry, APN, Stuart L. Goldberg, MD, Stefan Faderl

Blood (2017) 130 (Supplement 1): 5050.

https://doi.org/10.1182/blood.V130.Suppl_1.5050.5050

Published: 2017

Journal Articles

Management of adults with T-cell lymphoblastic leukemia

David I. Marks, Clare Rowntree

Blood (2017) 129 (9): 1134–1142.

https://doi.org/10.1182/blood-2016-07-692608

Published: 2017

Journal Articles

Characteristics, Outcomes and Treatment of Patients with T-Cell Prolymphocytic Leukemia (T-PLL) - Single-Center Experience

Etsuko Aoki, MDPhD, Preetesh Jain, MBBS, MDDM, PhD, Alessandra Ferrajoli, MD, Zeev Estrov, MD, Michael Keating, MBBS, Susan M. O'Brien, MD, William G. Wierda, MD PhD, Nitin Jain, MD, Philip A Thompson, MBBS, Elias Jabbour, MD, Sherry Pierce, BSN, BA, Chitra Hosing, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MD, Tapan M. Kadia, MD

Blood (2016) 128 (22): 2997.

https://doi.org/10.1182/blood.V128.22.2997.2997

Published: 2016

Journal Articles

Phase II Study of Hyper-CVAD Plus Nelarabine in Previously Untreated Adult T-Cell Acute Lymphoblastic Leukemia and T-Lymphoblastic Lymphoma

Blood (2016) 128 (22): 177.

https://doi.org/10.1182/blood.V128.22.177.177

Published: 2016

Journal Articles

Prognostic Parameters in Adults with Acute Lymphoblastic Leukemia at Second Complete Response

Caner Saygin, MD, Nikolaos Papadantonakis, MD PhD, Ryan D Cassaday, MD, Michaela Liedtke, MD, Katrina Fischer, MD, Tamara J. Dunn, MD, Bhumika Patel, MD, Sean Hobson, Cassie Zimmerman, Jaime Lynn Fensterl, MS, MBA, Ronald M. Sobecks, MD, Matt Kalaycio, MD FACP, Mikkael A. Sekeres, MD MS, Sudipto Mukherjee, MD, PhD, M.P.H., Aaron T. Gerds, MD MS, Betty K. Hamilton, MD, Hetty E. Carraway, MD MBA, Anjali S. Advani, MD

Blood (2016) 128 (22): 1603.

https://doi.org/10.1182/blood.V128.22.1603.1603

Published: 2016

Journal Articles

PRC2 Mutations Induce Resistance to Conventional Chemotherapy By Inhibiting Mitochondrial Apoptosis in T-Cell Acute Lymphoblastic Leukemia

Blood (2016) 128 (22): 604.

https://doi.org/10.1182/blood.V128.22.604.604

Published: 2016

Journal Articles

Clinical Characteristics of Philadelphia Positive T-Cell Lymphoid Leukemias - (de novo and blast phase CML)

Preetesh Jain, MBBS, MDDM, PhD, Hagop M. Kantarjian, MD, Elias J. Jabbour, MD, Rashmi Kanagal-Shamanna, MD, Keyur P. Patel, MD PhD, Sara Emogene DellaSala, BS, Sherry Pierce, BSN, BA, Guillermo Garcia-Manero, MD, Gautam Borthakur, MD, Farhad Ravandi, MD, Susan M. O'Brien, MD, Jorge E. Cortes, MD

Blood (2016) 128 (22): 5436.

https://doi.org/10.1182/blood.V128.22.5436.5436

Published: 2016

Journal Articles

Bridging to Second Allogeneic Peripheral Blood Stem Cell Transplantation with Nelarabine in a Patient with Multiply Relapsed/Refractory T-Cell ALL

Jacqueline Baptista, RN, APN, Eris Tollkuci, PharmD, Sunita Nathan, MD, John J. Maciejewski, MD PhD, Melissa L. Larson, MD, Gorgun Akpek, MD MHS

Blood (2016) 128 (22): 5200.

https://doi.org/10.1182/blood.V128.22.5200.5200

Published: 2016

NARROW

How I treat newly diagnosed T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma in children

CXCR4 Inhibition with BL-8040 in Combination with Nelarabine in Patients with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia / Lymphoblastic Lymphoma

Characteristics and Clinical Outcomes of Patients with Acute Lymphoblastic Leukemia with KMT2A ( MLL ) Rearrangement

CXCR4 Blockade By BL-8040 in T Cell Acute Lymphoblastic Leukemia Decreases Mitochondrial Mass and Induces Non-Apoptotic Cell Death

Pediatric-Inspired Chemotherapy Incorporating Pegaspargase Is Safe and Results in High Rates of MRD Negativity in Adults Ages 18-60 with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

The Impact of Minimal Residual Disease (MRD) Status at Day 28 in Predicting Relapse in Adults with Acute Lymphoblastic Leukemia in the Real World Setting

The CXCR4 Antagonist, BL8040, Is Highly Active Against Human T-ALL in Preclinical Models

Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) for Children and Young Adults with T-Cell Acute Lymphoblastic Leukemia (T-ALL) Treated at Investigator Discretion: A Report from Children's Oncology Group (COG) AALL0434

Daratumumab in Combination with Vincristine or Nelarabine As Effective Salvage Therapy for Patients with Acute Lymphoblastic Leukemia at High Risk of Relapse

Children's Oncology Group (COG) AALL0434: Successful Disease Control without Cranial Radiation in Newly Diagnosed T Lymphoblastic Lymphoma (T-LL)

RAS and TP53 , Not NOTCH1 , Can Predict Survival in Adults with Acute T-Cell Lymphoblastic Leukemia Treated with Hypercvad

Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia in Real-World US Practices

Outcomes with Augmented Hyper-CVAD (AHCVAD), a Pediatric Inspired HCVAD-Based Regimen, for Adults Younger Than 50 Years of Age with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

Management of adults with T-cell lymphoblastic leukemia

Characteristics, Outcomes and Treatment of Patients with T-Cell Prolymphocytic Leukemia (T-PLL) - Single-Center Experience

Phase II Study of Hyper-CVAD Plus Nelarabine in Previously Untreated Adult T-Cell Acute Lymphoblastic Leukemia and T-Lymphoblastic Lymphoma

Prognostic Parameters in Adults with Acute Lymphoblastic Leukemia at Second Complete Response

PRC2 Mutations Induce Resistance to Conventional Chemotherapy By Inhibiting Mitochondrial Apoptosis in T-Cell Acute Lymphoblastic Leukemia

Clinical Characteristics of Philadelphia Positive T-Cell Lymphoid Leukemias - (de novo and blast phase CML)

Bridging to Second Allogeneic Peripheral Blood Stem Cell Transplantation with Nelarabine in a Patient with Multiply Relapsed/Refractory T-Cell ALL

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only